Mylan N.V. (MYL) Upgraded by BidaskClub to “Buy”
BidaskClub upgraded shares of Mylan N.V. (NASDAQ:MYL) from a hold rating to a buy rating in a research report released on Friday.
MYL has been the topic of several other research reports. Zacks Investment Research upgraded shares of Mylan N.V. from a sell rating to a hold rating in a report on Tuesday, August 1st. Mizuho reiterated a buy rating and issued a $37.00 price target on shares of Mylan N.V. in a report on Tuesday, October 24th. Royal Bank Of Canada set a $41.00 price target on shares of Mylan N.V. and gave the company a hold rating in a report on Sunday, July 16th. J P Morgan Chase & Co reissued an overweight rating and set a $48.00 price objective (up previously from $44.00) on shares of Mylan N.V. in a research report on Friday, October 6th. Finally, Citigroup Inc. set a $42.00 price objective on Mylan N.V. and gave the company a buy rating in a research report on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $41.21.
Shares of Mylan N.V. (MYL) opened at 38.24 on Friday. The company has a market cap of $20.51 billion, a P/E ratio of 30.91 and a beta of 1.30. The stock’s 50 day moving average is $35.29 and its 200 day moving average is $36.23. Mylan N.V. has a 12 month low of $29.39 and a 12 month high of $45.87.
Mylan N.V. (NASDAQ:MYL) last announced its earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.08). The company had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3 billion. Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The company’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.16 earnings per share. On average, analysts anticipate that Mylan N.V. will post $4.59 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Mylan N.V. (MYL) Upgraded by BidaskClub to “Buy”” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://theolympiareport.com/2017/10/31/mylan-n-v-myl-upgraded-by-bidaskclub-to-buy.html.
Institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its stake in shares of Mylan N.V. by 19.8% during the 2nd quarter. FMR LLC now owns 813,267 shares of the company’s stock valued at $31,572,000 after purchasing an additional 134,258 shares during the period. Swiss National Bank grew its stake in shares of Mylan N.V. by 3.1% during the 2nd quarter. Swiss National Bank now owns 1,661,842 shares of the company’s stock valued at $64,513,000 after purchasing an additional 50,100 shares during the period. Vivaldi Asset Management LLC bought a new stake in shares of Mylan N.V. during the 2nd quarter valued at about $5,098,000. Advisors Capital Management LLC grew its stake in shares of Mylan N.V. by 4.7% during the 2nd quarter. Advisors Capital Management LLC now owns 86,329 shares of the company’s stock valued at $3,351,000 after purchasing an additional 3,854 shares during the period. Finally, Mn Services Vermogensbeheer B.V. grew its stake in shares of Mylan N.V. by 508.8% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 73,842 shares of the company’s stock valued at $2,867,000 after purchasing an additional 61,712 shares during the period. Institutional investors and hedge funds own 72.03% of the company’s stock.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.